Covid19COVAGERTNCT04947943
Geriatric Care for Older People Hospitalised for COVID-19
An observational study of Covid19, run by University Hospital, Montpellier at 1 site in France.
Trial summary
Current COVID-19 pandemic implies regular treatment adaptation by physician, according to scientific publication evolution. Older adults are particularly affected by COVID-19, with the higher severe form prevalence and the higher mortality rate. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Covid19
- How many people
- 230 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jun 2021to 30 Dec 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: Older adults aged 65 years and over, hospitalised in the conventional or the geriatric COVID-19 hospitalisation unit during the first COVID-19 wave in the Montpellier University Hospital
Who may be able to join
- adult age 65 years or over
- hospitalised for COVID-19 in one of the two hospitalisation unit (conventional or geriatric) during the first COVID19 wave
Who cannot join
- refusal to give the access to her/his medical record
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Impact of Geriatric Care in the Treatment of Older People Hospitalised for COVID-19
Current COVID-19 pandemic implies regular treatment adaptation by physician, according to scientific publication evolution. Older adults are particularly affected by COVID-19, with the higher severe form prevalence and the higher mortality rate. Furthermore older peoples are at high risk of complications cascade, due to the SARS-Voc-2 infection but also because of chronic diseases decompensation. If risk factors in this population have been identified, specific treatments to reduce complications or to be curative are less known. However geriatric care, thanks to its holistic approach, could reduce these complications and improve survival.
Our study aims to determine if geriatric care provided in geriatric COVID-19 hospitalisation units improves survival of older people (aged 65 years and over) at one month in comparison with conventional COVID-19 hospitalisation unit during the first wave in the Montpellier University Hospital. Secondary objectives are to determine if clinical characteristics of older patients are different between conventional and geriatric COVID-19 hospitalisation units, to assess influence of clinical characteristics of older patients on their survival, and to determine wich treatment have been delivered for older people during the COVID-19 pandemic first wave in our hospital in view of bibliographic data available at this time.
Read more
COVAGERT is a monocentric, descriptive, observational and retrospective study, including all older adults aged 65 years and over hospitalised in the geriatric COVID-19 and the conventional COVID-19 units of the Montpellier University Hospital during the first wave of the SARS-Cov-2 pandemic (between March 1th 2020 and September 1th 2020). Principal outcome is the survival one months after the RT-PCR positive test. Some data about treatments, medical history, socio-demographic and clinical characteristics will be collected from the medical record.
Statistical analysis will be performed using univariate and multivariate regressions according to the study's objectives.
Results will be useful to determine the bring of geriatric care during the current pandemic, but also to highlight the importance of multidisciplinary assessment in this complex disease and for further emergency medical challenges.
- Conditions
- Covid19
- Keywords
- COVID-19, Comprehensive geriatric assessment (CGA), Older adults
- Medical subject headings
- COVID-19
What is being measured
The primary outcome is the main question the study is designed to answer.
survival one month after positive SARS Cov 2 RT-PCR test
survival one month after positive SARS Cov 2 RT-PCR test
Measured: day 1
Secondary outcomes (3)
number of delivered treatments
delivered treatments
Measured: day 1
type of clinical characteristics
type of clinical characteristics
Measured: day 1
type of socio-demographic characteristics
type of socio-demographic characteristics
Measured: day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2021
- Study start1 Jun 2021
- Primary completion1 Dec 2021
- Study completion30 Dec 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Covid19Studies of the same condition, open and under way.
- More trials run by University Hospital, MontpellierThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 230 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Montpellier
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Miot stéphanie, PH, Study director, University Hospital, Montpellier
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04947943
- Sponsor's protocol ID
- RECHMPL21_0372
- Acronym
- COVAGERT
- Status last verified
- Apr 2022
- First submitted
- 30 Jun 2021
- Last updated
- 12 Apr 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: NC
Study at a glance
From the registry record, last updated by the sponsor on 12 Apr 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Geriatric Care in the Treatment of Older People Hospitalised for COVID-19
- ClinicalTrials.gov ID
- NCT04947943
- Acronym / sponsor ID
- COVAGERT / RECHMPL21_0372
- Conditions
- Covid19
- Keywords
- COVID-19, Comprehensive geriatric assessment (CGA), Older adults
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 230 participants (actual)
- Lead sponsor
- University Hospital, MontpellierUniversity, hospital or other
- Study start
- 1 Jun 2021 (actual)
- Primary completion
- 1 Dec 2021 (actual)
- Study completion
- 30 Dec 2021 (actual)
- First posted
- 1 Jul 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Current COVID-19 pandemic implies regular treatment adaptation by physician, according to scientific publication evolution. Older adults are particularly affected by COVID-19, with the higher severe form prevalence and the higher mortality rate. Furthermore older peoples are at high risk of complications cascade, due to the SARS-Voc-2 infection but also because of chronic diseases decompensation. If risk factors in this population have been identified, specific treatments to reduce complications or to be curative are less known. However geriatric care, thanks to its holistic approach, could reduce these complications and improve survival.
Our study aims to determine if geriatric care provided in geriatric COVID-19 hospitalisation units improves survival of older people (aged 65 years and over) at one month in comparison with conventional COVID-19 hospitalisation unit during the first wave in the Montpellier University Hospital. Secondary objectives are to determine if clinical characteristics of older patients are different between conventional and geriatric COVID-19 hospitalisation units, to assess influence of clinical characteristics of older patients on their survival, and to determine wich treatment have been delivered for older people during the COVID-19 pandemic first wave in our hospital in view of bibliographic data available at this time.
COVAGERT is a monocentric, descriptive, observational and retrospective study, including all older adults aged 65 years and over hospitalised in the geriatric COVID-19 and the conventional COVID-19 units of the Montpellier University Hospital during the first wave of the SARS-Cov-2 pandemic (between March 1th 2020 and September 1th 2020). Principal outcome is the survival one months after the RT-PCR positive test. Some data about treatments, medical history, socio-demographic and clinical characteristics will be collected from the medical record.
Statistical analysis will be performed using univariate and multivariate regressions according to the study's objectives.
Results will be useful to determine the bring of geriatric care during the current pandemic, but also to highlight the importance of multidisciplinary assessment in this complex disease and for further emergency medical challenges.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- Older adults aged 65 years and over, hospitalised in the conventional or the geriatric COVID-19 hospitalisation unit during the first COVID-19 wave in the Montpellier University Hospital
Key inclusion criteria (2 listed)
- adult age 65 years or over
- hospitalised for COVID-19 in one of the two hospitalisation unit (conventional or geriatric) during the first COVID19 wave
Key exclusion criteria (1 listed)
- refusal to give the access to her/his medical record
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
survival one month after positive SARS Cov 2 RT-PCR test
Time frame: day 1
survival one month after positive SARS Cov 2 RT-PCR test
3 secondary outcomes
number of delivered treatments
Time frame: day 1
type of clinical characteristics
Time frame: day 1
type of socio-demographic characteristics
Time frame: day 1
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Apr 2022.
- Individual participant dataSharing planned: Undecided. NC
Related trials for Covid19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Miot stéphanie, PH study director
University Hospital, Montpellier
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid19, run by University Hospital, Montpellier at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
survival one month after positive SARS Cov 2 RT-PCR test (time frame: day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Apr 2022.